S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
NASDAQ:IMRX

Immuneering (IMRX) Stock Price, News & Analysis

$6.15
-0.05 (-0.81%)
(As of 03/1/2024 ET)
Today's Range
$6.08
$6.33
50-Day Range
$5.52
$7.80
52-Week Range
$4.56
$14.29
Volume
76,126 shs
Average Volume
47,451 shs
Market Capitalization
$180.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.20

Immuneering MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
228.5% Upside
$20.20 Price Target
Short Interest
Bearish
12.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Immuneering in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.84) to ($1.93) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.06 out of 5 stars

Medical Sector

791st out of 951 stocks

Pharmaceutical Preparations Industry

359th out of 432 stocks


IMRX stock logo

About Immuneering Stock (NASDAQ:IMRX)

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

IMRX Stock Price History

IMRX Stock News Headlines

Immuneering Corp Class A
Revolutionary Device Redefines Cancer Detection
Discover the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Buy Rating on Immuneering Ahead of Key Drug Data Release
Buy Rating on Immuneering Ahead of Key Drug Data Release
Immuneering Corporation
Oppenheimer Keeps Their Buy Rating on Immuneering (IMRX)
Piper Sandler Keeps Their Buy Rating on Immuneering (IMRX)
See More Headlines
Receive IMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/01/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMRX
Fax
N/A
Employees
67
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.20
High Stock Price Target
$25.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+231.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-50,510,000.00
Pretax Margin
-5,163,499.50%

Debt

Sales & Book Value

Annual Sales
$320,000.00
Book Value
$4.16 per share

Miscellaneous

Free Float
22,537,000
Market Cap
$178.55 million
Optionable
Not Optionable
Beta
-0.78

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Benjamin J. Zeskind M.B.A. (Age 42)
    Ph.D., Co-Founder, President, CEO & Director
    Comp: $898.42k
  • Mr. Robert J. Carpenter M.B.A. (Age 78)
    M.S., Co-Founder & Chair Emeritus
    Comp: $83.17k
  • Dr. Brett M. Hall Ph.D. (Age 56)
    Chief Scientific Officer
    Comp: $867.92k
  • Ms. Mallory Morales CPA (Age 40)
    Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer
  • Ms. Paula George CPA
    Director of Accounting & Operations and Assistant Corporate Controller
  • Mr. Michael D. Bookman J.D. (Age 36)
    Chief Legal Officer & Secretary
  • Ms. Leah R. Neufeld (Age 52)
    Chief People Officer
  • Dr. Peter King Ph.D.
    Head of Discovery & VP
  • Dr. Praveen Nair Ph.D.
    Head of Translational Pharmacology & VP
  • Mr. Harold E. Brakewood (Age 59)
    Chief Business Officer














IMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Immuneering stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immuneering in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IMRX shares.
View IMRX analyst ratings
or view top-rated stocks.

What is Immuneering's stock price target for 2024?

5 brokerages have issued twelve-month target prices for Immuneering's stock. Their IMRX share price targets range from $14.00 to $25.00. On average, they predict the company's share price to reach $20.20 in the next twelve months. This suggests a possible upside of 228.5% from the stock's current price.
View analysts price targets for IMRX
or view top-rated stocks among Wall Street analysts.

How have IMRX shares performed in 2024?

Immuneering's stock was trading at $7.35 at the beginning of the year. Since then, IMRX stock has decreased by 16.3% and is now trading at $6.15.
View the best growth stocks for 2024 here
.

When is Immuneering's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our IMRX earnings forecast
.

How were Immuneering's earnings last quarter?

Immuneering Co. (NASDAQ:IMRX) posted its quarterly earnings results on Monday, November, 8th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.10. The company earned $0.48 million during the quarter, compared to analysts' expectations of $0.70 million.

What ETF holds Immuneering's stock ?

Range Cancer Therapeutics ETF holds 13,232 shares of IMRX stock, representing 1.36% of its portfolio.

When did Immuneering IPO?

(IMRX) raised $105 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities served as the underwriters for the IPO.

Who are Immuneering's major shareholders?

Immuneering's stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (11.54%), Price T Rowe Associates Inc. MD (11.54%), Citadel Advisors LLC (7.10%), Vanguard Group Inc. (3.67%), Goldman Sachs Group Inc. (1.56%) and Goldman Sachs Group Inc. (1.56%). Insiders that own company stock include Ann E Berman, Benjamin J Zeskind, Biren Amin, Brett Matthew Hall, Laurie Keating, Michael Bookman and Scott Barrett.
View institutional ownership trends
.

How do I buy shares of Immuneering?

Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMRX) was last updated on 3/1/2024 by MarketBeat.com Staff